Galmed is a clinical-stage biopharmaceutical company focusing on the development and commercialization of oral therapy for treating liver diseases... Read more
Galmed is a clinical-stage biopharmaceutical company focusing on the development and commercialization of oral therapy for treating liver diseases... Read more
News
Apr 02, 2025
Marketscreener
Galmed Pharmaceuticals: Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024
Mar 20, 2025
Marketscreener
Galmed Pharmaceuticals: Galmed Pharmaceuticals Ltd. Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in Nash/Mash Combination Therapy
Nov 14, 2024
Marketscreener
Galmed Pharmaceuticals: Galmed Pharmaceuticals Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024
Sep 25, 2024
LD Micro
Press Release: Galmed Pharmaceuticals : Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology
Sep 19, 2024
Benzinga
Galmed Pharmaceuticals: Galmed Pharmaceuticals Stock Is Soaring Thursday: Here's Why
Sep 19, 2024
StreetInsider
Press Release: Galmed Pharmaceuticals : Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases
Jun 05, 2024
MarketScreener
Galmed Pharmaceuticals: Galmed Pharmaceuticals : C/o Meitar Law Offices 16 Abba Hillel Silver Rd., Ramat Gan, 5250608 Form 6 K
Apr 04, 2024
PR Newswire
Galmed Pharmaceuticals: Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023
Mar 18, 2024
Pharmabiz
Galmed Pharmaceuticals: Galmed Pharma receives European patent for combination of Aramchol with Resmetirom to treat NASH and liver fibrosis
Nov 22, 2023
MarketScreener
Galmed Pharmaceuticals: Galmed Pharmaceuticals : Consolidated Financial Statements - Form 6-K
Galmed Pharmaceuticals Competitors
1
2
3
4
5
6
7
8
9
10